Eclectic Associates Inc. ADV lowers holdings in Danaher Co. (NYSE:DHR)

Eclectic Associates Inc. ADV reduced its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 13.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 887 shares of the conglomerate’s stock after selling 139 shares during the quarter. The holdings of Eclectic Associates Inc. ADV’s holdings in Danaher were worth $247,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DHR. Tsfg LLC raised its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the first quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new position in shares of Danaher during the fourth quarter valued at approximately $42,000. 79.05% of shares are held by hedge funds and other institutional investors.

The Wall Street analyst weighs in

Several research analysts recently commented on DHR shares. Leerink Partners raised their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday, September 6th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Stephens initiated coverage on shares of Danaher in a report on Tuesday. They issued an “overweight” rating and a $315.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Moderate Buy” and a consensus price target of $282.12, according to MarketBeat.

Check out our latest analysis of DHR

Danaher stock fell 0.2%

Shares of DHR stock traded down $0.49 during trading hours on Friday, hitting $270.03. The company had a trading volume of 1,132,669 shares, compared to its average volume of 2,759,666. The firm has a fifty day moving average price of $271.07 and a 200 day moving average price of $258.56. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04, and a current ratio of 1.43. The stock has a market cap of $200.01 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. it has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR – Get Free Report ) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. In the same quarter last year, the firm earned $2.05 EPS. Danaher’s revenue fell 2.9% year over year. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher announces dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a dividend of $1.08 on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insiders place their bets

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This represents a 0.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a decrease of 0.00 % in the stock holding. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of shares are held by insiders.

Danaher profile

(Free report)

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services worldwide. The Biotechnology segments provide bioprocess technologies, consumables and services that advance, accelerate and integrate drug development and manufacturing; cell line and cell culture media development services; cell culture media, process fluids and manufacturing buffers, chromatography resins, filtration technologies, aseptic fill finishing; disposable hardware and supplies and services such as design and installation of complete manufacturing suites; laboratory filtration, separation and purification; laboratory-scale protein purification and analytical tools; reagents, membranes and services; and filtration solutions for health care.

Featured stories

Want to see what other hedge funds own DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Danaher Co. (NYSE:DHR – Free Report).

Get news and reviews for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.